Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 103

Sunesis Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Sunesis Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Sunesis Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Sunesis Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Sunesis Pharmaceuticals, Inc. - Brief Sunesis Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sunesis Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Sunesis Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Sunesis Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Sunesis Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Sunesis Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Sunesis Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Sunesis Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Sunesis Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Sunesis Pharmaceuticals, Inc.; Sunesis Pharmaceuticals, Inc. - Key Therapeutics; Sunesis Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Sunesis Pharmaceuticals, Inc. - News; Sunesis Pharmaceuticals, Inc. - Latest Updates; Sunesis Pharmaceuticals, Inc. - Pipeline; Sunesis Pharmaceuticals, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Sunesis Pharmaceuticals, Inc. Snapshot
Sunesis Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Sunesis Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Sunesis Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc. – Pipeline Products Glance
Sunesis Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc. – Drug Profiles
BIIB024
SNS-032
SNS-314
Vosaroxin
Vosaroxin + Cytarabine
Sunesis Pharmaceuticals, Inc. – Pipeline Analysis
Sunesis Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Sunesis Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Sunesis Pharmaceuticals, Inc. – Recent Pipeline Updates
Sunesis Pharmaceuticals, Inc. - Dormant Projects
Sunesis Pharmaceuticals, Inc. – Company Statement
Sunesis Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 26, 2011: Sunesis To Host Conference Call To Discuss Corporate Updates And VALOR Poster Presented At ASCO 2011
Feb 23, 2011: Sunesis Receives FDA Fast Track Designation For Vosaroxin In AML
Jul 20, 2011: Sunesis Announces Publication Of Phase Ib Data Of Vosaroxin In Relapsed Or Refractory Acute Leukemia
Mar 10, 2011: Sunesis Wins European Patent Covering Vosaroxin Clinical Formulation
Jun 06, 2011: Sunesis Announces Presentation Of Adaptive Study Design For Vosaroxin Phase III VALOR Trial In AML At ASCO 2011
May 05, 2011: Sunesis Announces Publication Of Nonclinical Data Demonstrating Activity Of Vosaroxin In Acute Myeloid Leukemia Blasts
May 05, 2011: Sunesis Announces Publication Of Nonclinical Data Demonstrating Activity Of Vosaroxin In Combination With Cytarabine In Acute Myeloid Leukemia Blasts
Apr 04, 2006: Sunesis Presents Data On Anti-Cancer Compound SNS-032 At American Association For Cancer Research Meeting
Aug 03, 2011: Sunesis Receives US Patent Covering Vosaroxin Use To Treat Leukemia
Financial Deals Landscape
Sunesis Pharmaceuticals, Inc., Deals Summary
Sunesis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Sunesis Pharmaceuticals Extends Research Collaboration With Johnson & Johnson
Sunesis Pharmaceuticals Extends Research Collaboration With J&JPRD
Licensing Agreements
Materia Enters Into Licensing Agreement With Sunesis Pharmaceuticals
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Biogen Idec
Equity Offering
Sunesis Pharmaceuticals Files Registration Statement For Public Offering Of Common Stock For $20 Million
Sunesis Pharmaceuticals Completes Initial Public Offering Of $42 Million
Asset Transactions
Sunesis Pharmaceuticals Sells LFA-1 Inhibitor Program To SARcode
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Sunesis Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Sunesis Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Sunesis Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Sunesis Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Sunesis Pharmaceuticals, Inc. – Phase III, H2 2011
Sunesis Pharmaceuticals, Inc. - Phase II, H2 2011
Sunesis Pharmaceuticals, Inc. - Phase I, H2 2011
Sunesis Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Sunesis Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Sunesis Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Sunesis Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Sunesis Pharmaceuticals, Inc., Subsidiaries
Sunesis Pharmaceuticals, Inc., Deals Summary
Sunesis Pharmaceuticals Extends Research Collaboration With Johnson & Johnson
Sunesis Pharmaceuticals Enters Into An Agreement With Biogen Idec
Sunesis Pharmaceuticals Enters Into Research Collaboration With Merck
Sunesis Pharmaceuticals Extends Research Collaboration With J&JPRD
Materia Enters Into Licensing Agreement With Sunesis Pharmaceuticals
Millennium Enters Into Licensing Agreement With Sunesis Pharmaceuticals
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Carmot Therapeutics
CyDex Enters Into Licensing Agreement With Sunesis Pharmaceuticals
Sunesis Pharmaceuticals Enters Into Licensing Agreement With SARcode
Sunesis Pharmaceuticals Enters Into Research and License Agreement With University Of California
Sunesis Pharmaceuticals Enters Into Licensing Agreement With SARcode For LFA-1
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Bristol-Myers Squibb
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Biogen Idec
Sunesis Pharmaceuticals Files Registration Statement For Public Offering Of Common Stock For $20 Million
Sunesis Pharmaceuticals Completes Public Offering Of $15.5 Million
Sunesis Pharmaceuticals Completes First Tranche Of Private Placement For $10.7 Million
Sunesis Pharmaceuticals Completes Private Placement Of $28.5 Million
Sunesis Pharmaceuticals Completes Private Placement Of $15 Million
Sunesis Pharmaceuticals Completes Second Tranche Of Private Placement For $5 Million
Sunesis Pharmaceuticals Completes Public Offering Of $21 Million
Sunesis Pharmaceuticals Completes Private Placement Of $45 Million
Sunesis Pharmaceuticals Completes Initial Public Offering Of $42 Million
Sunesis Pharmaceuticals Sells LFA-1 Inhibitor Program To SARcode

List of Figures
Sunesis Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Sunesis Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Sunesis Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Sunesis Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Sunesis Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile